Steminent Biotherapeutics (ROCO:7729) EV-to-FCF : -3.71 (As of Apr. 13, 2025)

Steminent Biotherapeutics EV-to-FCF Chart

Competitive Comparison of Steminent Biotherapeutics's EV-to-FCF

For the Biotechnology subindustry, Steminent Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Steminent Biotherapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Steminent Biotherapeutics's EV-to-FCF falls into.

Steminent Biotherapeutics EV-to-FCF Calculation

Steminent Biotherapeutics's EV-to-FCF for today is calculated as:

Steminent Biotherapeutics's current Enterprise Value is NT$844.52 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Steminent Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-227.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steminent Biotherapeutics  (ROCO:7729) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Steminent Biotherapeutics's PE Ratio (TTM) for today is calculated as:

Steminent Biotherapeutics's share price for today is NT$19.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Steminent Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-3.230.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Steminent Biotherapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Steminent Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Steminent Biotherapeutics Business Description